ST266
ST266 is a biological therapy with 10 clinical trials. Currently 1 active trials ongoing. Historical success rate of 66.7%.
Success Metrics
Based on 6 completed trials
Phase Distribution
Phase Distribution
5
Early Stage
5
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
66.7%
6 of 9 finished
33.3%
3 ended early
1
trials recruiting
10
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Study to Assess the Safety, Tolerability, and Preliminary Efficacy of ST266 in Infants With Necrotizing Enterocolitis (NEC)
Evaluation of the Effectiveness of ST266 Ophthalmic Drops Compared to Placebo to Treat Allergic Conjunctivitis
ST266 Eyedrops for the Treatment of Persistent Corneal Epithelial Defects
Safety and Tolerability Study of IV ST266 in COVID-19 Subjects
ST266 Eye Drops for the Treatment of Persistent Corneal Epithelial Defects
Clinical Trials (10)
Study to Assess the Safety, Tolerability, and Preliminary Efficacy of ST266 in Infants With Necrotizing Enterocolitis (NEC)
Evaluation of the Effectiveness of ST266 Ophthalmic Drops Compared to Placebo to Treat Allergic Conjunctivitis
ST266 Eyedrops for the Treatment of Persistent Corneal Epithelial Defects
Safety and Tolerability Study of IV ST266 in COVID-19 Subjects
ST266 Eye Drops for the Treatment of Persistent Corneal Epithelial Defects
Safety, Efficacy and Treatment Regimen Study of ST266 in Subjects With Moderate to Severe Periodontitis
Study of ST266 in Diabetic Subjects With Deep Burns Managed With Skin Grafts
ST266 Versus Standard Care In Treating Partial Thickness Burns
Study of ST266 Eye Drops in Treating Dry Eye
Study of ST266 Versus Saline in Treating Skin Irritation From Radiation
All 10 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 10